伊贝沙坦治疗原发性高血压的临床疗效及安全性观察

目的评价伊贝沙坦治疗原发性高血压的有效性和安全性。方法采用随机、对照法观察伊贝沙坦治疗原发性高血压8周的疗效。70例原发性高血压患者随机分为两组,分别服用伊贝沙坦或非洛地平8周。观察血压变化及不良反应。结果两组治疗前后收缩压、舒张压的下降均有显著性差异(P<0.01),伊贝沙坦组有效率为74.3%,非洛地平组有效率为71.4%,组间比较差异无显著性(P>0.05)。两组治疗前后心率及各项实验室检测结果无显著性变化。结论伊贝沙坦是新型的ARB类药物,在治疗原发性高血压的过程中安全有效,患者能很好耐受。

The Clinical Curative Effect and Safety for Irbesartan on Essential Hypertension

Objective To evaluate the efficacy and safety of essential hypertension with irbesartan.Methods A randomized,double blind study was carried out on 70 patients with essential hypertension.Patients were divided randomly into two groups and given either irbesartan(irbesartan group) or felodipine(felodipine group ) for 8 weeks.To observe the blood pressure change and adverse reactions.Results Both systolic pressure and diastolic pressure is fallen in the two groups before and after treatment,There was a statistically significant differenc(eP<0.01).The average reduction in blood pressure readings for the two treatment groups were 74.3% and 71.4% respectively.No significant differences were found between two groups(P >0.05).No changes of HR were found throughout the study.No significant changes were found for routine blood examination,liver and renal functions,or electrocardiography after treatment.Conclusion Irbesartan is a new type of ARB,which has effective treatment in essential hypertension.It can be tolerated bythe patients.